QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.32
+2.52%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$31.85M
MomentumView details →
1D Return
+2.52%
YTD Return
−95.39%
RSI (14)
53.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
Market Cap
$31.85M
RSI (14)
53.3
MomentumView details →
1D Return
+2.52%
YTD Return
−95.39%
SummaryUpdated Jun 1, 2026
Quince Therapeutics, Inc. (NASDAQ:QNCX) is a biopharmaceutical company founded in 2012 and headquartered in South San Francisco, California. Originally incorporated as Cortexyme, Inc., the company rebranded to Quince Therapeutics in August 2022 following a strategic pivot in its research focus. The company went public in May 2019 and currently operates as a clinical-stage biotechnology firm specializing in precision therapeutics for debilitating and rare diseases, with a particular emphasis on bone-targeting drug delivery technologies.
Similar companies
Latest newsMore news →
Quince Therapeutics, Inc. received a notice from Nasdaq on August 31, 2026, stating that it no longer complies with the minimum bid price requirement under Rule 5450(b)(1)(A) for continued listing on the Nasdaq Global Market, and the company is evaluating options to regain compliance and has applied to transfer to the Nasdaq Capital Market.10h agoCharles Ryan departed as President of Quince Therapeutics, Inc., effective September 8, 2026, and is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023.9d agoQuince Therapeutics completed a private placement raising $115 million in gross proceeds, with potential additional proceeds of up to $83 million from warrant exercise.22d ago